In clinical practice for the treatment of chronic myeloid leukemia, second generation of tyrosine kinase inhibitors such as Nilotinib (NIL) specific and potent inhibitor of the BCR/ABL kinase and Dasatinib (DAS) a inhibitor of BCR/ABL and Src family kinase were developed to clinically overcome imatinib resistance. In this study we wanted to test the ability of some antioxidants such Resveratrol (RES) or a new recombinant mitochondrial manganese containing superoxide dismutase (rMnSOD) or δ-tocotrienol (δ-TOCO) to interact with DAS and NIL on viability, reactive oxygen species (ROS) production, lipid peroxidation and apoptosis. To test the possible mechanisms of action of such antioxidants, we utilized N-acetyl-L-cysteine (NAC) a specific inhibitor ROS production or PP1 a specific Src tyrosine kinase inhibitor or BAPTA a specific chelator of intracellular calcium. Our data demonstrated: 1) RES, rMnSOD, δ-TOCO and NAC, at dose used, significantly reduced the intracellular levels of MDA induced by DAS or NIL 2) RES, rMnSOD and δ-TOCO increased the intracellular ROS levels. 3) The increase ROS levels is related to higher levels of oligonucleosomesi induced by DAS and NIL and that NAC significantly reduced this activity. Interestingly, our data showed that apoptotic activity of DAS and NIL have significantly increased the production of oligonucleosomes by triggering excessive ROS generation as well as functionality of SERCA receptors. This article is protected by copyright. All rights reserved.

Damiano, S., Montagnaro, S., Puzio, M.V., Severino, L., Pagnini, U., Barbarino, M., et al. (2018). Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells. JOURNAL OF CELLULAR BIOCHEMISTRY, 119(6), 4845-4854 [10.1002/jcb.26686].

Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells

Barbarino, Marcella;Cesari, Daniele;Giordano, Antonio;
2018-01-01

Abstract

In clinical practice for the treatment of chronic myeloid leukemia, second generation of tyrosine kinase inhibitors such as Nilotinib (NIL) specific and potent inhibitor of the BCR/ABL kinase and Dasatinib (DAS) a inhibitor of BCR/ABL and Src family kinase were developed to clinically overcome imatinib resistance. In this study we wanted to test the ability of some antioxidants such Resveratrol (RES) or a new recombinant mitochondrial manganese containing superoxide dismutase (rMnSOD) or δ-tocotrienol (δ-TOCO) to interact with DAS and NIL on viability, reactive oxygen species (ROS) production, lipid peroxidation and apoptosis. To test the possible mechanisms of action of such antioxidants, we utilized N-acetyl-L-cysteine (NAC) a specific inhibitor ROS production or PP1 a specific Src tyrosine kinase inhibitor or BAPTA a specific chelator of intracellular calcium. Our data demonstrated: 1) RES, rMnSOD, δ-TOCO and NAC, at dose used, significantly reduced the intracellular levels of MDA induced by DAS or NIL 2) RES, rMnSOD and δ-TOCO increased the intracellular ROS levels. 3) The increase ROS levels is related to higher levels of oligonucleosomesi induced by DAS and NIL and that NAC significantly reduced this activity. Interestingly, our data showed that apoptotic activity of DAS and NIL have significantly increased the production of oligonucleosomes by triggering excessive ROS generation as well as functionality of SERCA receptors. This article is protected by copyright. All rights reserved.
2018
Damiano, S., Montagnaro, S., Puzio, M.V., Severino, L., Pagnini, U., Barbarino, M., et al. (2018). Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells. JOURNAL OF CELLULAR BIOCHEMISTRY, 119(6), 4845-4854 [10.1002/jcb.26686].
File in questo prodotto:
File Dimensione Formato  
Effects of antioxidants on apoptosis-Damiano-2018.pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1030360